Rasburicase: A review of its use in the management of anticancer therapy-induced hyperuricaemia

Drugs

Volumn 66, Issue 4, 2006, Pages 529-545

  Oldfield, Vicki ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Hyperuricaemia; Pharmacodynamics; Pharmacokinetics; Rasburicase; Therapeutic use; Tolerability; Tumour lysis syndrome

Indexed keywords

ALLOPURINOL; RASBURICASE;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERURICEMIA; MUCOSA INFLAMMATION; NAUSEA; NEPHRITIS; PH; RASH; RESPIRATORY DISTRESS; REVIEW; URIC ACID BLOOD LEVEL; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; URATE OXIDASE;

EID: 33645739675     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666040-00008     Document Type: Review

References (32)

1. McGraw-Hill's access medicine: Harrison's online [online]. Available from URL: http://www.accessmedicine.com [Accessed 2005 Nov 22]
2. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004 Oct; 127 (1): 3-11
3. Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002 Apr; 3 (4): 433-42
4. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricaemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003; 44 (1): 77-83
5. Bickert B, Reilly A. Pediatric tumor lysis syndrome. J Pharm Pract 2004; 17 (6): 447-54
6. Jeha S, Pui CH. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib Nephrol 2005; 147: 69-79
7. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004 Apr 15; 116 (8): 546-54
8. GlaxoSmithKline UK. Zyloric® (allopurinol) tablets 100mg, 300mg [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2005 Nov 24]
9. Pea F. Pharmacology of drugs for hyperuricemia: mechanisms, kinetics and interactions. Contrib Nephrol 2005; 147: 35-46
10. Jacob F, Drelon E, Neefe J, et al. New drug to lower uric acid levels in healthy volunteers: advances on prevention and control of hyperuricemia in malignancies? [abstract no. 1464]. 87th Annual Meeting of the American Association for Cancer Research; 1996 Apr 20-24; Washington, DC, 214
11. Sanofi-Synthelabo Inc. Elitek® (rasburicase) prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda [Accessed 2005 Nov 8]
12. Sanofi-Synthelabo. Summary of product characteristics: Fasturtec® (rasburicase) [online]. Available from URL: http://www.emea.eu.int/humandocs/ PDFs/EPAR/fasturtec/H-331-PI-en.pdf [Accessed 2005 Nov 8]
13. European Medicines Agency. Scientific discussion [online]. Available from URL: http://www.emea.eu.int/index/indexh1.htm [Accessed 2005 Nov 18]
14. Cheson BD, Dutcher BS. Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol 2005; 3 (2): 117-24
15. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001 Feb 1; 19 (3): 697-704
16. Lascombes F, Sommelet D, Gebhard F, et al. High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS) [abstract no. 4019]. Blood 1998 Nov 15; 92 Suppl. 1 (2): 237b
17. Mahmoud HH, Czerniak R, Auvrignon A, et al. Pharmacokinetics of recombinant urate oxidase SR29142 and anti-SR29142 antibodies in patients with cancer [abstract no. O-145]. Med Pediatr Oncol 1998 Oct; 31: 230
18. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001 May 15; 97 (10): 2998-3003
19. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003 Dec 1; 21 (23): 4402-6
20. Wang LY, Shih LY, Chang H, et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006; 115 (1-2): 35-8
21. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek®), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005 Jan; 19 (1): 34-8
22. Bosly A, Pinkerton CR, McCowage G, et al. Recombinant urate oxidase (rasburicase) is safe and effective in managing hyperuricemia in children and adults: results of a multi-national compassionate use trial. Blood 2002 Nov 16; 100 (Part 1): 556-7
23. Shin HY, Kang HJ, Park ES, et al. Recombinant urate oxidase (rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea. Pediatr Blood Cancer 2005 Aug 25
24. Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 2003 Apr; 11 (4): 249-57
25. National Comprehensive Cancer Network. Practice guidelines in oncology - v.1.2005: non-Hodgkin's lymphoma [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf [Accessed 2005 Dec 5]
26. National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology - v.1.2006: acute myeloid leukaemia [online]. Available from URL: http://www.nccn.org [Accessed 2005 Nov 24]
27. Montesinos P, Martin G, Perez-Sirvent M, et al. Identification of risk factors for tumour lysis syndrome in patients with acute myeloid leukaemia: development of a prognostic score [abstract no. 1843 plus poster]. American Society of Hematology 47th Annual Meeting; 2005 Dec 10-13; Atlanta (GA)
28. Nabi Biopharmaceuticals. Aloprim® (allopurinol sodium) for injection. Product information [online]. Available from URL: http://www.nabi.com/images/ prescribinginfo/aloprim%20PI%202003.pdf [Accessed 2005 Dec 6]
29. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Francaise d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol 2002 May; 13 (5): 789-95
30. Holdsworth MT, Nguyen P. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm 2003 Nov 1; 60 (21): 2213-22, quiz 2223-4
31. Smalley RV, Guaspari A, Haase-Statz S, et al. Allopurinol: intravenous use for prevention and treatment of hyperuricaemia. J Clin Oncol 2000; 18 (8): 1758-63
32. Bertrand Y, Auvrignon A, Nelken B, et al. SFCE (Société Francaise des Cancers de l'Enfant) recommendations for the management of tumour lysis syndrome (TLS): a validation survey [abstract no. 3122 plus poster]. American Society of Hematology 47th Annual Meeting; 2005 Dec 10-13; Atlanta (GA)